Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
19 March 2021Website:
http://www.gaintherapeutics.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:23:09 GMTDividend
Analysts recommendations
Institutional Ownership
GANX Latest News
BETHESDA, Md., June 28, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that interim-CEO and current CFO Gene Mack will host a business and corporate update call on Monday, July 1, 2024, beginning 8:30am ET pre-market open.
Data demonstrates improvement in cognitive function in GBA1 Parkinson's disease model in addition to reversal of motor function deficits Data demonstrates improvement in cognitive function in GBA1 Parkinson's disease model in addition to reversal of motor function deficits
Gain Therapeutics (NASDAQ: GANX ) stock is falling on Friday following the pricing of its shares in a public offering. This public offering has Gain Therapeutics selling 7,116,547 shares and pre-funded warrants for 1,031,602 shares.
BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock (or pre-funded warrants in lieu thereof) in an underwritten public offering. Gain expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and pre-funded warrants offered in the offering. All of the securities are being offered by the Company.
New data demonstrating improvement of cognitive performance after treatment with GT-02287 in preclinical model of GBA1 Parkinson's disease New data demonstrating improvement of cognitive performance after treatment with GT-02287 in preclinical model of GBA1 Parkinson's disease
Gain Therapeutics (GANX) lacks the necessary combination of key ingredients for a potential earnings beat in its upcoming report. Be ready for the key expectations.
A recent decrease in value for Gain Therapeutics (GANX) has resulted in the formation of a hammer chart pattern, suggesting that the stock has found a level of support. With an increase in earnings estimate revisions and the potential for a trend reversal, the stock may see positive movement in the near future.
Gain Therapeutics (GANX) is currently considered oversold, suggesting that the intense selling pressure on the stock may be diminishing. Additionally, with Wall Street analysts increasingly raising their earnings estimates, there is potential for a turnaround in the stock's performance soon.
Gain Therapeutics' Former CEO and current Board Member Eric Richman to participate in fireside chat hosted by Public Ventures President Lou Basenese and Aberdeen Investment Management President Jeb Terry, Sr. Gain Therapeutics' Former CEO and current Board Member Eric Richman to participate in fireside chat hosted by Public Ventures President Lou Basenese and Aberdeen Investment Management President Jeb Terry, Sr.
Gain Therapeutics, Inc. (GANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
What type of business is Gain Therapeutics?
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
What sector is Gain Therapeutics in?
Gain Therapeutics is in the Healthcare sector
What industry is Gain Therapeutics in?
Gain Therapeutics is in the Biotechnology industry
What country is Gain Therapeutics from?
Gain Therapeutics is headquartered in United States
When did Gain Therapeutics go public?
Gain Therapeutics initial public offering (IPO) was on 19 March 2021
What is Gain Therapeutics website?
https://www.gaintherapeutics.com
Is Gain Therapeutics in the S&P 500?
No, Gain Therapeutics is not included in the S&P 500 index
Is Gain Therapeutics in the NASDAQ 100?
No, Gain Therapeutics is not included in the NASDAQ 100 index
Is Gain Therapeutics in the Dow Jones?
No, Gain Therapeutics is not included in the Dow Jones index
When does Gain Therapeutics report earnings?
The next expected earnings date for Gain Therapeutics is 09 August 2024